Capricor Therapeutics shares closed 58 percent higher on August 14 after regulators indicated a willingness to review new data for the company's Duchenne muscular dystrophy treatment, deramiocel. While the stock saw a significant bounce, this recovery only offsets a small portion of the losses incurred following a negative advisory panel vote earlier in the summer.
The regulatory path remains complex. An advisory panel previously voted 9 to 3 against the effectiveness of the drug for Duchenne-related cardiomyopathy, leaving the stock down 66 percent from its July 24 peak. Management now aims to shift focus toward skeletal muscle function, planning to submit 24-month open-label extension data to support the case. The Food and Drug Administration has agreed to review this amendment, which will delay the original August 22 decision deadline.
Investors should remain cautious despite the positive market reaction. The FDA review of this new submission does not guarantee approval. Questions persist regarding the statistical methodology and the lack of a randomized, placebo-controlled comparison for the 24-month data. The company also faces ongoing challenges, including a distribution dispute and limited revenue, as it narrows its operational focus to preserve cash.
While the amendment keeps the possibility of approval alive, the market rally appears to have outpaced current regulatory certainty. Capricor must prove the reliability of its evidence package to clear the remaining hurdles. Investors are watching closely to see if this additional data effectively addresses concerns raised by the advisory panel regarding the drug’s performance.